|
KMID : 0378019950380100057
|
|
New Medical Journal
1995 Volume.38 No. 10 p.57 ~ p.64
|
|
|
Clinical Evaluation of Nizatidine in Acute Gastritis and Acute Aggravation of Chronic Gastritis
|
|
김범수/Kim, Bum Soo
박성민/전윤창/이병원/전우규/김병익/정을순/Park, Sung Min/Jun, Yoon Chang/Lee, Byung Won/Jun, Woo Kyu/Kim, Byung Ick/Jung, Eul Soon
|
|
|
Abstract
|
|
|
Histamine H2-receptors are highly effective therapy for gastritis in the treatment of ulcer, and are extensively used in daily practice.
Nizatidine, a histamine H2-bloker, has a potent suppressive effect on gastric acid. It has an excellent efficacy in the treatment of peptic ulcers and reflux esophagitis. This benefit is widely confirmed in clinical settings. It has induced by taurocholic acid-histamine or taurocholic acid-serotonin in rat acute gastritis models. These data suggest that nizatidine is as effective as other H2-blockers for the treatment of gastritis by suppressing gastric acid secretion.
To confirm the clinical benefit of nizatidine for acute gastritis and acute aggravation of chronic gastritis, a open-label comparative study was undertaken with cimetidine, an H2-bloker which is also effective for the disease as a control drug. The results are reported herein.
In a total of 30 patients enrolled in this study, 15 patients were assigned to the nizatidine group and other 15 patients to the cimetidine group.
According to the result of the overall clinical evaluation, the global improvement rates(improvem-ent or better evaluation) were 80% in nizatidine group and 73% in the cimetidine group with no significant difference between two groups. As for global safety, rates of safety were shown to be very high in both groups.
This results suggest that nizatidine, 150mg at a time, twice daily after breakfast and at bedtime, has similar effect to cimetidine in the treatment of acute gastritis and acute aggravation phase in chronic gastritis.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|